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Chronic Acute Hepatitis 
A Review 
Klaus .\nselm, M.D.* 
The current literature concerning chronic acute hepatitis is reviewed. The clinical 
picture, morphology, labcnatory data and etiology are discussed. It is pointed out 
that tnuch work is still lo be done toward fully understanding this disease. A pro-
gram of treatment is suggested. 
A group of young women with 
chronic liver disease and hypergamma-
globulinemia was described by Kunkel 
and .Ahrens' in 1951. In the following 
years the term chronic active hepatitis-
(C.-\H) was applied to this entity. The 
;ipiv;irance of LE cells was described in 
similar groups of patients.-' * It was 
then apparent that many of these pa-
tients had systemic clinical features 
usually not seen in viral hepatitis or cir-
fhosis. In 1956, Mackay et aF intro-
duced the term "lupoid hepatitis" in 
their description of a group of seven 
patients and suggested an antigen-anti-
hody reaction was an important ctio-
'ogic factor in this disease. In a later 
'description Mackay" included lupoid 
hepatitis in a group of 69 patients with 
^AH and put forth the following char-
^teristics: 
' persistent fluctuating activity for 
more than six months. 
- activity manifested by elevation 
of serum transaminases. 
'^'^lon of Gastroenterology 
3. elevation of serum gamma globu-
lin by 2 to 6 grams. 
4. morphologic piecemeal necrosis. 
l\niphoid infiltration and fibrosis. 
5. various serum aulo-antibody re-
actions, 
6. suppression by immune suppres-
sive drugs in the early stage of 
the disease. 
Because of the variability of the 
clinical and histological picture, chronic 
active hepatitis has been described un-
der a variety of names. .\ few examples 
are cryptogenic cirrhosis." chronic liver 
disease in young women,** plasma cell 
hepatitis." progressive hepatitis.'" active 
juvenile cirrhosis," subacute hepati-
tis.'- and auto-immune hepatitis.' -'' 
Clinical Features 
The term chronic active hepatitis 
includes a heterogenous group of pa-
tients with a spectrum of disease vary-
ing from viral hepatitis to cirrhosis. 
However, a past history of viral hepati-
tis can be obtained in only a small num-
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ber of patients.' - The age of onset 
ranges from the first to the seventh dec-
ade, but the majority of patients are 
first seen in their early teens or twen-
ties.""'* There is a predominance of 
female over male patients" ' ' and a 
role for estrogens has been suggested 
in the pathogenesis of this disease. 
Jaundice and insidiously developing 
fatigue are predcmiinant clinical symp-
toms.'' often accompanied by low 
grade fever, anorexia and malaise. Sys-
temic involvement is frequent. Mac-
lachlan'"' observed arthralgias and 
arthritis in 16 of a group of 20 patients 
with CAH. There was involvement of 
the heart in three and of the lungs in 
five. Other systemic complications in-
cluded generalized lymphadenopathy, 
glomerulonephritis, generalized convul-
sions, ulcerative colitis, leucopenia. 
thrombocytopenia, and urticaria. Simi-
lar observations were made by other 
authors ' '' The liver is usually firm and 
tender, and the spleen is frequently en-
larged. Spider angiomata are noted 
with ascites in 3()'~^  of observed 
cases.'^  
Four variants were suggested by 
SchafTncr and Klion.' ' althmigh all are 
understood to represent the same dis-
ease; 
1 C'.\H iKcurring in postmenopau-
-.il ^vomen. with a more rapid 
and progressive course towards 
cirrhosis and death. 
2. C.-\H m young girls near puberty 
with associated menstrual ab-
normalities and a marked sensi-
tivity to estrogens. 
3. CAH in prepubertal boys with a 
more rapidly progressive course 
than in girls of a similar age 
group. 
4. CAH in young women with a 
higher incidence of systerr c 
manifestations, including positi e 
LE cell preparations, butterrly 
rash, pleurisy and hemolv ic 
anemia. This group of patients 
led to the use of the term "lu-
poid hepatitis."-'" There has been 
considerable controversy whether 
these patients constitute a separ-
ate entity.'^ 
Laboratory Findings 
Levels of transaminases usually 
lluctuate widely," the alkaline phos-
phatase is generally elevated'^ while the 
bilirubin may be normal. SchafTner and 
Klion' ' found it hard to correlate these 
laboratory data with the clinical pic-
ture and the morphology of the liver 
Most impressive is the elevation of the 
gamma globulins,""' ' - " ''' appai . ntl\ 
with IgG as the main contributor.""" 
IgM may be moderately increased,"" 
while measurements of IgA may range 
from a decreased level'""* to a mender-
ate increase.'" Patients with a positive 
antinuclear factor tend to have a more 
significant increase of IgM. 
Positive LE preparations and anti-
nuclear factor are found frequently as 
expressions of nonspecific antigen-anti-
body reactions. Maclachlan'-' reported 
positive LE cells in 14 of 19 patient^  
and positive homogenous antinuclear 
factor in 16 of 18 patients. Mackay and 
Wood-" observed positive LE cells in 
22 of 72 patients. Mackay et al* a'' 
tempted to separate lupoid hepauii^  
from CAH. They found 10% posit'^ ' 
homogenous antinuclear factor a"^  
30% positive speckled antinuvlei-' 
factor in chronic active hepatitis 
contrasted with 32% positive hom^ " 
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genous and 41% positive speckled an-
tinuclear factor in lupoid hepatitis. 
False positive serologic tests for syph-
ilid have also been reported.'"' 
Specific circulating antibodies against 
the individual liver cell have never been 
rei irted," '^ although antibodies direct-
ed against proliferating bileduct cells 
h. been observed.-' Non-organ-spe-
cific antibodies directed against mito-
chondria, present in virtually all pa-
tients with primary bUiary cirrhosis, 
were found in 28% of patients with 
CAH;-- smooth muscle antibodies were 
found in 48% of CAH;-' antibodies 
to cytoplasmic antigens in 12 of 15 
patients.-* 
Pathology 
Four pathologic processes take place 
in chronic active hepatitis, all closely 
linked, though one might predominate: 
1. Necrosis of individual liver cells 
al the periphery of the liver lobule 
with subsequent destruction of 
the limiting end plate.-' 
(Electron microscopic changes 
varying from cell to cell: focal 
cytoplasmic degeneration, hyper-
trophy and vesiculation of the 
endoplasmic reticulum and shed-
ding of the cytoplasm from the 
sinusoidal surface.'-'') 
2. Active fibroplasia around dam-
aged liver cells with newly form-
ed capillaries, proliferating bile 
ducts and septal formation by 
fibroblasts eventually leading to 
cirrhosis.-' 
-^ Accumulation of mononuclear 
cells deriving from the reticulo-
endothelial system after transition 
through macrophages. These 
cells contain gammaglobulin, 
demonstrable by immunofluores-
cence, and are thought to be the 
cause of the hypergammaglobu-
linemia-' (immunocytes). 
4. Active regeneration with multi-
nucleation of hepatocytes and 
nodule formation. 
Etiology 
The cause of chronic active hepati-
tis is not known and it is probable that 
this disease has several etiologic com-
ponents. Disturbances of hepatic circu-
lation, malnutrition and genetic factors 
have been considered. Mackay"--" be-
lieves that CAH represents the result 
of liver damage caused by viruses in 
persons with abnormal immune toler-
ance, particularly those with the ten-
dency to respond abnormally to the re-
lease of liver cell compounds. The 
autoimmune response then is perpetu-
ated because immunocytes continue to 
be stimulated by antigen from damaged 
liver cells. Evidence against this theory 
is the absence of demonstrable anti-
bodies against hepatocytes."' ' Popper-" 
does not believe in autoimmunity by 
direct action of circulating antibodies. 
He suggests that the autoimmune proc-
ess is initiated by complexes between 
antibodies and antigens, not necessar-
ily hepatic and that they are responsi-
ble for perpetuation of the process. 
The systemic features, often resembling 
systemic lupus erythematosis, arc 
caused by the same circulating anti-
gen-antibody complexes. Not under-
stood is the frequent occurrence of 
CAH leading to cirrhosis in patients 




No specific therapy against CAH is 
available. Results of therapy are diflfi-
cult to assess and controlled clinical 
trials are few in number. It is important 
to realize that therapy should not be 
guided by the morphology of liver biop-
sies nor by laboratory tests, but by the 
symptoms and clinical appearance of 
the patient. Immunosuppressive agents 
(steroids, Azathioprine, 6-Mercapto-
purine) will improve BSP excretion-** 
and will reduce the gammaglobulin, 
transaminase, and bilirubin levels.'"-^o-
'" '-' However, this therapy may not de-
lay the inexorable progress of the dis-
ease to cirrhosis and death. 
A suggested course of management-" 
includes: Activity and diet directed by 
the patient's symptoms; complications 
treated symptomatically in the usual 
fashion. More severe symptoms may 
respimd to Prednisone, started at 60 
mg daily (single dose) and gradually 
reduced over several months to 10-20 
mg daily. If symptoms cannot be con-
trolled, a trial with Azathioprine should 
be attempted, 50-150 mg daily. Occa-
sionally the combination of 5-10 mg of 
Prednisone with 25-50 mg of AzathiO' 
princ has been beneficial. 
Prognosis 
The natural history of chronic active 
hepatitis progresses to the complication 
of portal hypertension and hypersplen-
ism. The disease course is fluctuaiing 
but progressive and many patients die 
from hepatic failure and from bleeding 
esophageal varices. Mortality also oc-
curs from associated complication^ in-
cluding ulcerative colitis, septicemia, 
pyelonephritis and glomerulonephritis. 
The average survival from the time of 
diagnosis ranges from four to srven 
years."-''' Although the ultimate prog-
nosis of CAH is guarded, an occasional 
patient maintains symptomatic good 
health over a long period of time in 
spite of laboratory evidence of severe 
liver disease. If the prognosis of CAH 
is to be more hopeful, fundamental 
knowledge is necessary in the etiolog} 
and pathogenesis of this disease. 
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